Phthalocyanine Dye Conjugate Formulations for Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing phthalocyanine dye conjugates for photoimmunotherapy are prone to aggregation, which affects their stability and efficacy in targeting and killing specific cells, such as tumor cells, without damaging healthy cells.
Innovation Solution
Incorporating stabilizing agents, such as non-ionic surfactants like polysorbate 80 and protectants like trehalose, into the phthalocyanine dye-antibody conjugates, specifically cetuximab-IR700, to reduce or prevent aggregation under various stress conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phthalocyanine dye conjugates are used for photoimmunotherapy, then targeted cell killing capability is improved, but aggregation occurs reducing stability and efficacy
Solution Approach 1:
The patent introduces stabilizing agents as intermediary substances that mediate between the phthalocyanine dye conjugate and the aqueous environment. These stabilizing agents prevent direct harmful interactions between conjugate molecules, thereby preventing aggregation while maintaining the conjugate's targeted cell killing capability. The stabilizing agents act as protective intermediaries that maintain conjugate stability without interfering with the therapeutic function.
Solution Approach 2:
The patent modifies the chemical composition parameters of the conjugate formulation by incorporating specific stabilizing agents at controlled concentrations. This changes the physical-chemical parameters of the system, particularly the colloidal stability and aggregation behavior, while preserving the biological activity. The parameter change approach allows the conjugate to maintain both stability and efficacy simultaneously.
2Stability of the object's composition
If stabilizing agents are added to prevent aggregation, then conjugate stability is improved, but formulation complexity increases
Solution Approach 1:
The patent employs stabilizing agents that are relatively simple, well-characterized molecules with established safety profiles. These stabilizing agents can be easily incorporated into the formulation without requiring complex manufacturing processes or specialized equipment. The approach uses simple, readily available substances to achieve stability rather than complex engineered solutions.
Solution Approach 2:
The patent optimizes the concentration ranges of stabilizing agents to achieve effective stability with minimal formulation complexity. By establishing specific concentration parameters, the patent transforms a potentially complex formulation problem into a controlled parameter optimization problem, where simple adjustments in stabilizing agent concentration achieve the desired stability without requiring complex formulation designs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions maintain a high percentage of monomeric form of the conjugate, enhancing stability and efficacy by reducing aggregation, allowing for prolonged storage and effective photoimmunotherapy applications.
Implementation Method 1
the one or more stabilizing agents include a surfactant, such as a non-ionic surfactant or a zwitterionic surfactant
Implementation Method 2
the one or more stabilizing agents include a surfactant, such as a non-ionic surfactant or a zwitterionic surfactant, and/or a protectant
Data Source
AI summary
Provided are compositions containing a conjugate containing a phthalocyanine dye, including compositions containing stabilizing agents, such as non-ionic surfactants and/or protectants. In some aspects, the compositions result reduced aggregation of the conjugate due to agitation, temperature exposure, and/or pH. Also provided are articles of manufacture containing the compositions containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.